Literature DB >> 18602036

Evaluation of the guidelines for management of pancreatic branch-duct intraductal papillary mucinous neoplasm.

Raymond S Tang1, Benjamin Weinberg, David W Dawson, Howard Reber, Oscar J Hines, James S Tomlinson, Vinika Chaudhari, Steven Raman, James J Farrell.   

Abstract

BACKGROUND & AIMS: The 2006 Sendai Consensus Guidelines recommend surgical resection for all suspected branch-duct intraductal papillary mucinous neoplasm (BD-IPMN) greater than 3 cm irrespective of symptoms, and those less than 3 cm with worrisome features. We aimed to evaluate the surgical characteristics of these guidelines retrospectively in pathologically confirmed cases of BD-IPMN.
METHODS: IPMNs resected at our institution (1995-2006) were classified as main-duct predominant or branch-duct (BD) predominant based on preoperative imaging and postoperative histology. Resected BD-IPMNs were classified histologically: low risk (adenoma, borderline) and high risk (carcinoma in situ or invasive cancer). Clinical data (presence of symptoms, mural nodule, dilated pancreatic duct, and cyst size) were correlated with pathology.
RESULTS: Between 1995 and 2006, there were 204 patients who underwent surgical resection of pancreatic cysts. Sixty-one patients had IPMN including 31 with BD-IPMN. A total of 74.2% (23 of 31) of BD-IPMNs would have been recommended for surgical resection including 69.2% (18 of 26) of low-risk lesions and 100% (5 of 5) of high-risk lesions. All 8 cases of BD-IPMN that would have been recommended for nonsurgical management were low-risk lesions. The positive predictive value of the guidelines is 21.7% (95% confidence interval, 9.7%-41.9%). The negative predictive value is 100% (95% confidence interval, 67.6%-100.0%). Between 2000 and 2007, 351 patients with likely BD-IPMN were evaluated but not resected.
CONCLUSIONS: Implementation of the Consensus Guidelines to our single-institution, referral-based, surgical BD-IPMN population would have recommended resection of all histologically high-risk lesions. All lesions recommended for nonsurgical management were histologically low-risk lesions. For presumed BD-IPMNs less than 3 cm, the application of the Consensus Guidelines may reduce the resection rate for low-risk lesions.

Entities:  

Mesh:

Year:  2008        PMID: 18602036     DOI: 10.1016/j.cgh.2008.04.005

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  57 in total

1.  Clinicopathological characteristics and molecular analyses of multifocal intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Hanno Matthaei; Alexis L Norris; Athanasios C Tsiatis; Kelly Olino; Seung-Mo Hong; Marco dal Molin; Michael G Goggins; Marcia Canto; Karen M Horton; Keith D Jackson; Paola Capelli; Giuseppe Zamboni; Laura Bortesi; Toru Furukawa; Shinichi Egawa; Masaharu Ishida; Shigeru Ottomo; Michiaki Unno; Fuyuhiko Motoi; Christopher L Wolfgang; Barish H Edil; John L Cameron; James R Eshleman; Richard D Schulick; Anirban Maitra; Ralph H Hruban
Journal:  Ann Surg       Date:  2012-02       Impact factor: 12.969

2.  Circulating Leptin and Branched Chain Amino Acids-Correlation with Intraductal Papillary Mucinous Neoplasm Dysplastic Grade.

Authors:  Michele T Yip-Schneider; Rachel Simpson; Rosalie A Carr; Huangbing Wu; Hao Fan; Ziyue Liu; Murray Korc; Jianjun Zhang; C Max Schmidt
Journal:  J Gastrointest Surg       Date:  2018-09-13       Impact factor: 3.452

Review 3.  Novel Biomarkers for Pancreatic Cysts.

Authors:  Harkirat Singh; Kevin McGrath; Aatur D Singhi
Journal:  Dig Dis Sci       Date:  2017-02-14       Impact factor: 3.199

4.  Pancreatic Fluid Interleukin-1β Complements Prostaglandin E2 and Serum Carbohydrate Antigen 19-9 in Prediction of Intraductal Papillary Mucinous Neoplasm Dysplasia.

Authors:  Rachel E Simpson; Michele T Yip-Schneider; Katelyn F Flick; Huangbing Wu; Cameron L Colgate; C Max Schmidt
Journal:  Pancreas       Date:  2019-09       Impact factor: 3.327

5.  Fukuoka and AGA Criteria Have Superior Diagnostic Accuracy for Advanced Cystic Neoplasms than Sendai Criteria.

Authors:  Michael Sighinolfi; Susan Y Quan; Yvonne Lee; Alvaro Ibaseta; Kimberly Pham; Monica M Dua; George A Poultsides; Brendan C Visser; Jeffery A Norton; Walter G Park
Journal:  Dig Dis Sci       Date:  2017-01-23       Impact factor: 3.199

Review 6.  Pancreatic Cysts in the Elderly.

Authors:  Luis F Lara; Anjuli Luthra; Darwin L Conwell; Somashekar G Krishna
Journal:  Curr Treat Options Gastroenterol       Date:  2019-12

7.  Decision making for pancreatic resection in patients with intraductal papillary mucinous neoplasms.

Authors:  Bin Xu; Wei-Xing Ding; Da-Yong Jin; Dan-Song Wang; Wen-Hui Lou
Journal:  World J Gastroenterol       Date:  2013-03-07       Impact factor: 5.742

8.  Pancreatic cyst prevalence and the risk of mucin-producing adenocarcinoma in US adults.

Authors:  Timothy B Gardner; Lisa M Glass; Kerrington D Smith; Gregory H Ripple; Richard J Barth; David A Klibansky; Thomas A Colacchio; Michael J Tsapakos; Arief A Suriawinata; Gregory J Tsongalis; J Marc Pipas; Stuart R Gordon
Journal:  Am J Gastroenterol       Date:  2013-10       Impact factor: 10.864

9.  Consensus guidelines in the management of branch duct intraductal papillary mucinous neoplasm: a cost-effectiveness analysis.

Authors:  Edward S Huang; G Scott Gazelle; Chin Hur
Journal:  Dig Dis Sci       Date:  2009-10-16       Impact factor: 3.199

10.  Mucin-producing neoplasms of the pancreas: an analysis of distinguishing clinical and epidemiologic characteristics.

Authors:  Stefano Crippa; Carlos Fernández-Del Castillo; Roberto Salvia; Dianne Finkelstein; Claudio Bassi; Ismael Domínguez; Alona Muzikansky; Sarah P Thayer; Massimo Falconi; Mari Mino-Kenudson; Paola Capelli; Gregory Y Lauwers; Stefano Partelli; Paolo Pederzoli; Andrew L Warshaw
Journal:  Clin Gastroenterol Hepatol       Date:  2009-10-14       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.